News Search Results
Aug 21, 2025, 11:20 ET SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Alto Neuroscience
$17 from $33 and stated that ALTO-100's data raises questions around the Company's overall biomarker approach to CNS disorders and psychiatry. The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class
More news about: Faruqi & Faruqi, LLP
Aug 19, 2025, 13:05 ET Ategenos Emerges from Stealth to Debut First-Ever SmartPatch Platform Transforming the Economics of Medication Non-Adherence
populationsAtegenos is advancing a proprietary drug pipeline through the FDA's 505(b)(2) regulatory pathway across behavioral health, cardiovascular, CNS, and oncology indications. At the same time, the company is exploring external development partnerships with pharmaceutical manufacturers in three key
More news about: Ategenos Pharmaceuticals Inc.
Aug 18, 2025, 17:00 ET REGENXBIO Announces FDA Review Extension of BLA for RGX-121 to Treat Patients with MPS II
to the central nervous system (CNS). Delivery of the IDS gene within cells in the CNS could provide a permanent source of secreted iduronate-2-sulfatase (I2S) protein beyond the blood-brain barrier, allowing for long-term cross correction of cells throughout the CNS. RGX-121 expressed protein is
More news about: REGENXBIO Inc.
Aug 18, 2025, 09:00 ET Avixgen, a subsidiary of Dx&Vx, signs a licensing-out agreement worth USD 360 million with a U.S. biotech company for its next-generation drug delivery platform (ACP).
drugs, and secured results that improved motor function in damaged animals. This is evaluated as presenting a practical solution to the development of CNS (central nervous system) targeted therapeutics, which has been difficult to achieve with existing drug delivery technologies. Dx&Vx and Avixgen
More news about: Dx&Vx
Aug 16, 2025, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Alto Neuroscience, Inc. and Certain Officers - ANRO
pro-neurogenesis/neuroplasticity mechanism of action" and has stated that the Company "believe[s] binds a receptor not targeted by other [central nervous system ("CNS")] therapeutics, which would make it first-in-class if approved." On January 12, 2024, Alto filed a registration
More news about: Pomerantz LLP
Aug 15, 2025, 07:00 ET Novel Gene Therapy for ALS cleared for global trials in China and the U.S.
identified and characterized by Dr. Yichang Jia's group at Tsinghua University, upon delivery to the central nervous system (CNS), particularly motor neurons. This global Phase I/IIa trial will evaluate the safety and potential efficacy of SNUG01 and identify dosage for further
More news about: SineuGene Therapeutics
Aug 14, 2025, 09:04 ET SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Alto Neuroscience
$17 from $33 and stated that ALTO-100's data raises questions around the Company's overall biomarker approach to CNS disorders and psychiatry. The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class
More news about: Faruqi & Faruqi, LLP
Aug 14, 2025, 07:00 ET Corero Network Security Grants Exclusivity in Brazil to Forte Technology as Part of Regional Expansion
Corero Network Security, (AIM: CNS) (OTCQX: DDOSF), a recognized leader in DDoS protection and champion of adaptive, real-time service availability, today announced an exclusive channel-reseller
More news about: Corero Network Security
Aug 14, 2025, 07:00 ET Corero Network Security Concede Exclusividade No Brasil À Forte Technology Como Parte De Sua Expansão Regional
LONDRES, Reino Unido, 14 de agosto de 2025 /PRNewswire/ -- A Corero Network Security (AIM: CNS) (OTCQX: DDOSF), líder reconhecida em proteção contra ataques DDoS e disponibilidade adaptável de serviços em tempo real, anunciou hoje um acordo exclusivo
More news about: Corero Network Security
Aug 13, 2025, 13:06 ET Nuvalent to Present Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC at WCLC 2025 Presidential Symposium
for central nervous system (CNS) penetrance to improve treatment options for patients with brain metastases, and to avoid inhibition of the structurally related tropomyosin receptor kinase (TRK) family. Together, these characteristics have the potential to avoid TRK-related CNS adverse events seen with
More news about: Nuvalent, Inc.
Aug 13, 2025, 08:00 ET Apertura Gene Therapy Licenses Blood-Brain Barrier-Penetrant AAV Capsid to Multiple Partners Advancing Central Nervous System Treatments
Apertura's human transferrin receptor 1 capsid (TfR1 CapX) for their central nervous system (CNS) programs. A third venture-backed biotechnology company has entered into an Option Agreement with Apertura for multiple CNS indications.
More news about: Apertura Gene Therapy
Aug 13, 2025, 04:12 ET FPT, 베트남-한국 반도체 및 고급 인력 양성 분야 협력 강화
산업 수요와 국제 기준에 부합하는 프로그램을 운영하고 있다. 베트남-한국 기술 협력 강화 2016년에 한국에 진출한 FPT는 한국과 베트남에서 2천여 명의 직원을 고용해 Lg전자, LG CNS, 신한은행, 대구은행, 신세계아이앤씨 등 주요 고객사를 지원하고 있다. 가트너가 선정한 한국 내 200대 기술 기업(2020–2021년)에도 포함된 FPT는 한국에 진출한 베트남 기업 중 매출과 인력 규모에서 1위 기업이다. FPT 소개
More news about: FPT Corporation
Aug 12, 2025, 08:00 ET CRC Becomes Accredited Medidata Rave® EDC Partner
research organization, specializing exclusively in CNS disorders, including neurology, psychiatry, and analgesia. Combining innovative technology, deep scientific expertise, and personalized concierge support, CRC partners with sponsors, specialized sites, and CNS experts to deliver high-quality, efficient clinical
More news about: Cognitive Research Corporation
Aug 11, 2025, 16:17 ET Cohen & Steers Announces Preliminary Assets Under Management and Net Flows for July 2025
YORK, Aug. 11, 2025 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) today reported preliminary assets under management of $88.6 billion as of July 31, 2025,
More news about: Cohen & Steers, Inc.
Aug 11, 2025, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Alto Neuroscience, Inc. and Certain Officers - ANRO
pro-neurogenesis/neuroplasticity mechanism of action" and has stated that the Company "believe[s] binds a receptor not targeted by other [central nervous system ("CNS")] therapeutics, which would make it first-in-class if approved." On January 12, 2024, Alto filed a registration
More news about: Pomerantz LLP
Aug 08, 2025, 16:05 ET Cohen & Steers Announces Changes to Realty Indexes
YORK, Aug. 8, 2025 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) announced today pending changes to its Realty Majors Portfolio Index (RMP) and Global Realty Majors Portfolio Index (GRM), effective as of the close
More news about: Cohen & Steers, Inc.
Aug 08, 2025, 10:20 ET SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Alto Neuroscience
$17 from $33 and stated that ALTO-100's data raises questions around the Company's overall biomarker approach to CNS disorders and psychiatry. The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class
More news about: Faruqi & Faruqi, LLP
Aug 08, 2025, 08:03 ET HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Receipt of Final Clearance to Proceed to Closing of Dura Medical Acquisition from Florida's Agency for Health Care Administration (AHCA)
Florida Dura delivers a full range of precision psychiatry services for severe depression, PTSD and related CNS disorders, including Ketamine therapy and Transcranial Magnetic Stimulation (TMS), to veteran and civilian patients Acquisition expected
More news about: NRx Pharmaceuticals, Inc.
Aug 07, 2025, 09:00 ET Cipla Expands Fall River Operations in USA, Announces Upcoming Hiring for Various Roles
North America, and key regulated and emerging markets. Our strengths in the respiratory, anti-retroviral, urology, cardiology, anti-infective and CNS segments are well-known. Our 46 manufacturing sites around the world produce 50+ dosage forms and 1,500+ products using cutting-edge technology platforms
More news about: Cipla USA Inc.
Aug 07, 2025, 07:00 ET Firefly Fiber Broadband Selects Corero Network Security for Scalable DDoS Protection Across Expanding Infrastructure
Corero Network Security (AIM: CNS) (OTCQX: DDOSF), a recognized leader in DDoS protection and champion of adaptive, real-time service availability, today announced a new customer win
More news about: Corero Network Security
Aug 06, 2025, 10:45 ET Biomarkers Market to Grow at a CAGR of 12.3% from 2025 to 2032 | SkyQuest Technology Consulting
Comprehensive Test, which covers over 500 genes and supports precision oncology applications. Similarly, Alamar Biosciences launched the NULISAseq™ CNS Disease Panel 120 in March 2024, targeting early detection of neurodegenerative diseases using ultra-sensitive protein
More news about: SkyQuest Technology
Aug 06, 2025, 10:01 ET Pharmaceutical Suppositories Market is expected to generate a revenue of USD 2.74 Billion by 2032, Globally, at 5.91% CAGR: Verified Market Research®
Size By Type (Early Phase Development Services, Clinical Trial Services, Laboratory Services, Consulting Services), By Therapeutic Area (Oncology, CNS Disorders, Cardiovascular Diseases, Infectious Diseases, Metabolic Disorders), By End User (Pharmaceutical & Biopharmaceutical Companies, Medical
More news about: Verified Market Research
Aug 06, 2025, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Alto Neuroscience, Inc. and Certain Officers - ANRO
pro-neurogenesis/neuroplasticity mechanism of action" and has stated that the Company "believe[s] binds a receptor not targeted by other [central nervous system ("CNS")] therapeutics, which would make it first-in-class if approved." On January 12, 2024, Alto filed a registration
More news about: Pomerantz LLP
Aug 06, 2025, 08:05 ET Pulmatrix Announces Second Quarter 2025 Financial Results and Divestment Plan for Inhalation Assets
unmet medical needs using its patented iSPERSE™ technology. The Company's proprietary product pipeline includes treatments for central nervous system ("CNS") disorders such as acute migraine and serious lung diseases such as Chronic Obstructive Pulmonary Disease ("COPD") and allergic bronchopulmonary aspergillosis
More news about: Pulmatrix Inc.
Aug 06, 2025, 07:02 ET The U.S. FDA Granted Fast Track Designation to Dizal's Birelentinib for Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
growth of B-NHLs in cell lines and in animal models. In clinical studies, birelentinib exhibits favorable PK properties, good central nervous system (CNS) permeability, complete blockade of BCR signaling, and encouraging anti-tumor efficacy with good safety and tolerability in patients with B-NHL.
More news about: Dizal Pharmaceutical